Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Core Insights - Black Diamond Therapeutics presented real-world treatment outcomes for newly diagnosed non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations at the ESMO Congress 2024, highlighting a significant unmet need for effective therapies in this patient population [1][4] Treatment Analysis - Out of 11,434 sequenced cases of newly diagnosed and treatment-naïve EGFR mutant NSCLC, first-line treatment data was evaluated for 3,276 patients, revealing that 36% received osimertinib or afatinib, while 60% were treated with chemotherapy and/or immunotherapy [2] - Patients with non-classical EGFR mutations showed a median treatment discontinuation time of 6.0 months for osimertinib, 8.0 months for afatinib, and 4.2 months for chemotherapy, indicating limited efficacy and high toxicity associated with current treatments [3] Company Development - Black Diamond Therapeutics is advancing BDTX-1535, a fourth-generation EGFR TKI designed to target a broad spectrum of EGFR mutations, particularly non-classical mutations, and plans to disclose initial Phase 2 data in Q1 2025 [4][5] - The company aims to address the evolving landscape of EGFR mutations, which can be present in 20-30% of newly diagnosed NSCLC patients, with over 100 identified non-classical mutations [4]